NCT00715169View on ClinicalTrials.gov

Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

April 30, 2006

Conditions
Atherosclerosis
Interventions
DRUG

MLN1202

10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour

OTHER

Placebo

Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00715169 - Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease | Biotech Hunter | Biotech Hunter